CNA
CNA Financial Corporation
CNA's fundamentals are mixed, but it looks expensive: trading at 13x earnings, above its usual 11x. Its downside scenario is about three times its upside.
IREN
IREN Limited
There isn't enough reported data to score IREN yet.
CNA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| N/A | |
| N/A |
CNA's profitability is currently healthy, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like CNA.
IREN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| N/A | |
| N/A |
IREN's revenue and profitability are currently under pressure. Free cash flow and net leverage aren't meaningful measures for financial services companies like IREN.
CNA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.8x | $37.32 | -23% |
| Fair | 11x | $42.60 | -12% |
| Forward | 11x | $48.29 | — |
| Current | 13x | $48.29 | — |
| Expensive | 15x | $55.76 | +15% |
Historical ranges are pointers, not guarantees.
CNA's PE is in its expensive range at 13x. On analysts' estimates for next year's earnings, today's price would be 11x, in its fair range.
IREN PE Valuation
IREN has no meaningful PE right now: it lost money over the past year.
CNA Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Decline | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Moderate |
Analysts expect CNA's revenue to grow, but its earnings and profitability to decline.
IREN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
IREN has the edge over CNA on the outlook, with more favorable profitability expectations.
CNA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.59 | +21% |
| Q3 2026 | $3.79 | +3.8% |
| Q2 2026 | $4.55 | +42% |
| Q1 2026 | $4.47 | +36% |
| Q4 2025 | $4.69 | +33% |
| Q3 2025 | $3.65 | -24% |
| Q2 2025 | $3.21 | -32% |
| Q1 2025 | $3.28 | -28% |
| Q4 2024 | $3.52 | -21% |
CNA has the edge over IREN on earnings quality, reporting a profit while its opponent remains loss making.
IREN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.96 | -347% |
| Q2 2026 | -$2.22 | -988% |
| Q1 2026 | $0.51 | +$1.10 |
| Q4 2025 | $1.18 | +$1.62 |
| Q3 2025 | $1.60 | +$1.99 |
| Q2 2025 | $0.25 | +$0.45 |
| Q1 2025 | -$0.59 | -$0.43 |
| Q4 2024 | -$0.44 | -$0.15 |
IREN has swung to a loss: it lost $3.96 per share over the past year, after a profit the year before.
CNA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.8B | +0.1% |
| Q2 2026 | $3.8B | +3% |
| Q1 2026 | $3.7B | +1.4% |
| Q4 2025 | $3.8B | +3.8% |
| Q3 2025 | $3.8B | +5.5% |
| Q2 2025 | $3.7B | +5.6% |
| Q1 2025 | $3.6B | +5.3% |
| Q4 2024 | $3.7B | +5.2% |
CNA's revenue has grown year over year for 16 quarters in a row: $3.8B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.2% | -7.2 points |
| Q2 2026 | 11% | +0.4 points |
| Q1 2026 | 7.3% | -2.4 points |
| Q4 2025 | 9.9% | +9.3 points |
| Q3 2025 | 13% | +3.5 points |
| Q2 2025 | 10% | -1.2 points |
| Q1 2025 | 9.6% | -2.8 points |
| Q4 2024 | 0.6% | -13 points |
CNA has the edge over IREN on profitability, with a higher operating margin.
IREN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $228M | -5.1% |
| Q2 2026 | $137.2M | -27% |
| Q1 2026 | $144.8M | 0% |
| Q4 2025 | $184.7M | +59% |
| Q3 2025 | $240.3M | +355% |
| Q2 2025 | $187.3M | +230% |
| Q1 2025 | $144.8M | +168% |
| Q4 2024 | $116.1M | +176% |
IREN's revenue has held roughly level: $228M last quarter, down 5.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -82% | -50 points |
| Q2 2026 | -452% | -461 points |
| Q1 2026 | -161% | -180 points |
| Q4 2025 | -63% | -79 points |
| Q3 2025 | -32% | +57 points |
| Q2 2025 | 9% | +49 points |
| Q1 2025 | 19% | +8 points |
| Q4 2024 | 15% | +21 points |
IREN's operating margin was −82% last quarter, down 50 points from the same quarter a year ago.
CNA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $634M | -9.9% |
| Q2 2026 | $629M | +17% |
| Q1 2026 | $380M | -39% |
| Q4 2025 | $542M | -18% |
| Q3 2025 | $704M | -3.6% |
| Q2 2025 | $538M | -9.9% |
| Q1 2025 | $620M | +28% |
| Q4 2024 | $665M | +34% |
CNA has the edge over IREN on cash generation, producing positive trailing cash flow while its opponent burns cash.
IREN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.6B | -$1.6B |
| Q2 2026 | $482.2M | +2895% |
| Q1 2026 | -$873.8M | -$523.1M |
| Q4 2025 | -$468M | -$334M |
| Q3 2025 | -$38M | +$349.4M |
| Q2 2025 | $16.1M | +$179M |
| Q1 2025 | -$350.7M | -$128.7M |
| Q4 2024 | -$134M | -$105.2M |
IREN's free cash flow was −$2.5B over the past year, against −$507M the year before. Free cash flow isn't a meaningful measure for financial services companies like IREN.
CNA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +300K shares |
| 1 year | -0.1% | -300K shares |
| 3 years | -0.1% | -300K shares |
| 5 years | -0.3% | -700K shares |
| Available history | -0.2% | -500K shares |
CNA has the edge over IREN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $36M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $34M |
| Q4 2024 | — |
CNA spent $36M buying back its own shares over the past year, up 5.9% from the year before.
IREN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +26% | +82.4M shares |
| 1 year | +10% | +36.9M shares |
| 3 years | +511% | +333M shares |
| 5 years | +624% | +344M shares |
| Available history | +2346% | +382M shares |
IREN has 399M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
CNA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.9x | Healthy |
| Q2 2026 | 1.6x | Healthy |
| Q1 2026 | 1.5x | Healthy |
| Q4 2025 | 1.5x | Healthy |
| Q3 2025 | 2.2x | Moderate |
| Q2 2025 | 2.2x | Moderate |
| Q1 2025 | 2.1x | Moderate |
| Q4 2024 | 2.0x | Healthy |
CNA's net debt is about 1.9 years of its operating earnings (EBITDA), down from 2.2 years a year ago. Net leverage isn't a meaningful measure for financial services companies like CNA.
IREN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 157.6x | High |
| Q4 2025 | 22.2x | High |
| Q3 2025 | 4.1x | High |
| Q2 2025 | 2.0x | Moderate |
| Q1 2025 | 3.3x | Elevated |
| Q4 2024 | -4.6x | Net Cash |
| Q3 2024 | -16.7x | Net Cash |
| Q2 2024 | -15.9x | Net Cash |
IREN's net debt is more than 20 years of its operating earnings (EBITDA), up from 3.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like IREN.
CNA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.0 | Neutral |
| Stochastic | 35.9 | Neutral |
CNA's weekly RSI is 51 (neutral) and its Stochastic is 36 (neutral).
IREN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.3 | Neutral |
| Stochastic | 8.2 | Oversold |
IREN's weekly RSI is 33 (neutral) and its Stochastic is 8 (oversold).
CNA PE vs Financial Services Sector
| Metric | CNA | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 13x | 2.2% below |
| PE % | 68 | 63 | 5 pts above |
CNA is trading at 13x earnings, in line with the Financial Services sector's median of 13x.
IREN PE vs Financial Services Sector
| Metric | IREN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
IREN has no meaningful PE right now: it lost money over the past year.
CNA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $47.4 | 1.9% above |
| 20 week MA | $49.3 | 2% below |
| 50 week MA | $47.6 | 1.5% above |
| 100 week MA | $47.4 | 1.9% above |
| 200 week MA | $45.4 | 6.4% above |
CNA has the edge over IREN on trend strength, trading above more of its moving averages.
IREN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.8 | 35% below |
| 20 week MA | $36.2 | 46% below |
| 50 week MA | $42.8 | 54% below |
| 100 week MA | $32.0 | 39% below |
| 200 week MA | $19.1 | 2.1% above |
IREN has fallen below most of its moving averages, though it's still 2.1% above its 200-week average.
CNA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $44.5 | $38.6 | -13% |
| 2021 | $38.6 | $43.8 | +13% |
| 2022 | $43.8 | $41.9 | -4.4% |
| 2023 | $41.9 | $42.3 | +1.1% |
| 2024 | $42.3 | $48.4 | +14% |
| 2025 | $48.4 | $47.8 | -1.3% |
| 2026 YTD | $47.8 | $48.3 | +1.1% |
CNA has the edge over IREN on returns for 2026, with the stronger performance.
IREN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.8 | $17.2 | -31% |
| 2022 | $17.2 | $1.19 | -93% |
| 2023 | $1.19 | $7.15 | +501% |
| 2024 | $7.15 | $10.7 | +50% |
| 2025 | $10.7 | $40.3 | +276% |
| 2026 YTD | $40.3 | $19.5 | -52% |
IREN's yearly returns have swung widely, from +501% in 2023 to −93% in 2022. It's down 52% so far in 2026.